Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT06560606
Recruiting Observational

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

NCT06560606 · tracked via the Priya Life Science Netherlands tracker
Sponsor
The Hospital for Sick Children
Phase
Observational
Started
2018-08-24
Last updated
2024-08-19

Condition(s) studied

Juvenile Idiopathic Arthritis

Study summary

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: Cohort 1: - Biologic Basis of JIA * ≤18 years\* * Active objective arthritis suspected to be JIA or diagnosed with JIA within 6 months of enrolment * Treatment naïve except for NSAIDs, allowed to have received NSAIDS within 6 months of diagnosis Cohort 2 - Start Biologics * JIA diagnosis as per ILAR criteria (all subtypes) * ≤18 years\* * Active arthritis * For sJIA, active disease not necessarily with arthritis. * Time of start, restart or switch biologic therapy: e.g. failure, insufficient/partial response or intolerance Cohort 3 - Stop Biologics * JIA diagnosis as per ILAR criteria (all subtypes) * ≤18 years\* * Inactive disease * Discontinuing/tapering biologics for inactive disease Cohort 4: Extreme Phenotypes * Unexplained systemic inflammation with arthritis/arthralgia as a part of manifestations * High suspicion of genetic contribution * Severely affected patients with difficult to control disease (ie failure of multiple biologics) Exclusion Criteria: Cohort 1 : * Arthritis explained by another diagnosis * Joint injections as previous treatment less than 4 weeks prior to enrollment Cohort 2: * Arthritis explained by any other cause * Start on biologics as an indication for uveitis only Cohort 3: \- Tapering scheme \> 12 months to complete biologics stop Cohort 4: \- Arthritis explained by another diagnosis

Primary outcome measure(s)

Trial sites (19)

FacilityCityRegionStatus
Alberta Children's Hospital - University of Calgary Calgary Alberta Recruiting
Stollery Children's Hospital Edmonton Alberta Recruiting
BC Children's Hospital Vancouver British Columbia Recruiting
Children's Hospital Health Science Centre Winnipeg Winnipeg Manitoba Recruiting
Janeway Children's Hospital and Rehabilitation Centre St. John's Newfoundland and Labrador Recruiting
IWK Health Centre Halifax Nova Scotia Recruiting
McMaster Children's Hospital Hamilton Ontario Recruiting
Children's Hospital, London Health Sciences Centre London Ontario Recruiting
Children's Hospital of Eastern Ontario Ottawa Ontario Recruiting
The Hospital for Sick Children Toronto Ontario Recruiting
Montréal Children's Hospital Montreal Quebec Recruiting
University of Saskatchewan Saskatoon Saskatchewan Recruiting
Amalia Children's Hospital, Radboudumc Nijmegen Gelderland Recruiting
Sint Maartenskinderkliniek Boxmeer North Brabant Recruiting
Emma Children's Hospital, Amsterdam UMC Amsterdam North Holland Recruiting
Willem-Alexander Children's Hospital, LUMC Leiden South Holland Recruiting
Sophia Children's Hospital, EMC Rotterdam South Holland Recruiting
Beatrix Children's Hospital, UMCG Groningen Netherlands Recruiting
Wilhelmina Children's Hospital, UMCU Utrecht Netherlands Recruiting

More The Hospital for Sick Children trials in the Netherlands

Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block Recruiting
International Rare Histiocytic Disorders Registry (IRHDR) Recruiting

Other trials for the same condition

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Recruiting
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06560606 on ClinicalTrials.gov ↗ ← All trials in the Netherlands